Letermovir

Brand name: Prevymis

DILI Likelihood

Score E — Unlikely Hepatotoxin

Despite extensive use, there is no convincing evidence that this drug causes liver injury.

Single case reports may have been published, but they were largely unconvincing. The agent is not believed or is unlikely to cause liver injury.

Classification

Primary class Antimicrobial

Secondary class CMV

FDA approval 2017